Athena Bioscience gets FDA green light for Qdolo

Adults with pain that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate will soon have a new specialty opioid agonist to manage their pain.

The Food and Drug Administration has approved Athena Bioscience’s Qdolo (tramadol hydrochloride) oral solution 5mg/1mL C-IV.

"As an oral liquid, Qdolo gives physicians flexibility to titrate dosing precisely according to individual patients' needs," said Jeff Bryant, president and CEO of Athena Bioscience. "In addition, for patients with swallowing disfunction (dysphagia) or who simply have trouble swallowing pills, Qdolo provides an essential alternative to other forms of tramadol."

Qdolo will be available at chain, independent, and specialty pharmacies.